Skip to content
  • HOME
  • HIGHLIGHTS
  • COMPANY
  • PRESENTATION
  • NEWS
  • CONTACT

October 16, 2025

Ocumetics Webinar Replay: First-In-Human Study One-Month Postoperative Results Update (Oct 15, 2025)

Ocumetics Webinar Replay: First-In-Human Study One-Month Postoperative Results Update (Oct 15, 2025)

  • Ocumetics to Showcase First-In-human Results with Industry Leaders & Potential Strategic Partners at ASCRS Annual Meeting

    Key Highlights Early First-in-Human clinical results have drawn the attention of industry leaders and several of the largest vision care technology companies in the world. Ocumetics will leverage the conference to further engage with global strategic partners to accelerate development and commercialization efforts. Calgary, Canada – TheNewswire – April 1, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSV:V OTC) (OTCQB: OTCFF) (FRA:

    Continue reading
  • Ocumetics Achieves Breakthrough in Next-Generation Accommodating Intraocular Lens Design

    Key Highlights Breakthrough Accommodating Interocular Lens Design: The enhanced lens design introduces several novel concepts that are expected to improve substantially upon the consistency, durability, and manufacturability of the lens. Enhanced Performance with Greater Reliability: This next-generation technology is anticipated to deliver natural optical responsiveness and improved mechanical stability, supporting excellent vision across its full

    Continue reading
  • Ocumetics Announces Forbearance Agreement for $4 Million Secured Convertible Debentures and Provides LIFE Offering Update

    Calgary, Alberta – February 10, 2026 – TheNewswire – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is pleased to announce that the Corporation has entered into a forbearance agreement with the holders of secured convertible debentures (the “Debentures”) that were issued by the Corporation in May and June 2024 (see press release

    Continue reading
  • Ocumetics Reports Positive Three Month First-in-Human Results, Significantly De-Risking Its Accommodating Intraocular Lens Technology

    Continue reading
Previous123Next

TSX-V:OTC | OCTQB: OTCFF | FSE: 2QB0

Contact Information

#1250 – 639 5th Ave SW
Calgary AB T2P 0M9
Canada

Investor Relations

Vice President – Howard Group Inc
Dave Burwell – Send Email

© 2026 • Powered by Howard Group • Privacy Policy • Ocumetics Technology Corp
Page load link
Go to Top